1401 related articles for article (PubMed ID: 19008712)
21. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
[TBL] [Abstract][Full Text] [Related]
22. A rationale for treatment of endothelial dysfunction in hypertension.
Ruschitzka F; Corti R; Noll G; Lüscher TF
J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841
[TBL] [Abstract][Full Text] [Related]
23. Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells.
Yang Z; Xiaohua W; Lei J; Ruoyun T; Mingxia X; Weichun H; Li F; Ping W; Junwei Y
Am J Physiol Renal Physiol; 2010 Aug; 299(2):F336-46. PubMed ID: 20484295
[TBL] [Abstract][Full Text] [Related]
24. Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.
Yamamoto E; Kataoka K; Shintaku H; Yamashita T; Tokutomi Y; Dong YF; Matsuba S; Ichijo H; Ogawa H; Kim-Mitsuyama S
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2569-75. PubMed ID: 17932313
[TBL] [Abstract][Full Text] [Related]
25. Iptakalim ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
Li J; Long C; Cui W; Wang H
J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):60-9. PubMed ID: 22947433
[TBL] [Abstract][Full Text] [Related]
26. Iptakalim: a new or just another KCO?
Costa AD
Cardiovasc Res; 2009 Aug; 83(3):417-8. PubMed ID: 19515796
[No Abstract] [Full Text] [Related]
27. [Interventional effects of activating SUR2B/Kir6.1-type K
Zhao Y; Wang H
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2022 Nov; 38(6):604-610. PubMed ID: 37308403
[No Abstract] [Full Text] [Related]
28. Iptakalim hydrochloride protects cells against neurotoxin-induced glutamate transporter dysfunction in in vitro and in vivo models.
Yang YL; Meng CH; Ding JH; He HR; Ellsworth K; Wu J; Hu G
Brain Res; 2005 Jul; 1049(1):80-8. PubMed ID: 15932749
[TBL] [Abstract][Full Text] [Related]
29. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.
Mazzali M; Kanellis J; Han L; Feng L; Xia YY; Chen Q; Kang DH; Gordon KL; Watanabe S; Nakagawa T; Lan HY; Johnson RJ
Am J Physiol Renal Physiol; 2002 Jun; 282(6):F991-7. PubMed ID: 11997315
[TBL] [Abstract][Full Text] [Related]
30. Effects of allopurinol, a xanthine oxidase inhibitor, on renal injury in hypercholesterolemia-induced hypertensive rats.
Minami M; Ishiyama A; Takagi M; Omata M; Atarashi K
Blood Press; 2005; 14(2):120-5. PubMed ID: 16036490
[TBL] [Abstract][Full Text] [Related]
31. A role for uric acid in the progression of renal disease.
Kang DH; Nakagawa T; Feng L; Watanabe S; Han L; Mazzali M; Truong L; Harris R; Johnson RJ
J Am Soc Nephrol; 2002 Dec; 13(12):2888-97. PubMed ID: 12444207
[TBL] [Abstract][Full Text] [Related]
32. Red wine polyphenols prevent angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase.
Sarr M; Chataigneau M; Martins S; Schott C; El Bedoui J; Oak MH; Muller B; Chataigneau T; Schini-Kerth VB
Cardiovasc Res; 2006 Sep; 71(4):794-802. PubMed ID: 16822492
[TBL] [Abstract][Full Text] [Related]
33. Chemerin/ChemR23 signaling axis is involved in the endothelial protection by K(ATP) channel opener iptakalim.
Zhao RJ; Wang H
Acta Pharmacol Sin; 2011 May; 32(5):573-80. PubMed ID: 21516134
[TBL] [Abstract][Full Text] [Related]
34. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
35. Mangiferin alleviates hypertension induced by hyperuricemia via increasing nitric oxide releases.
Yang H; Bai W; Gao L; Jiang J; Tang Y; Niu Y; Lin H; Li L
J Pharmacol Sci; 2018 Jun; 137(2):154-161. PubMed ID: 29934052
[TBL] [Abstract][Full Text] [Related]
36. The new antihypertensive drug iptakalim activates ATP-sensitive potassium channels in the endothelium of resistance blood vessels.
Wang SY; Cui WY; Wang H
Acta Pharmacol Sin; 2015 Dec; 36(12):1444-50. PubMed ID: 26592519
[TBL] [Abstract][Full Text] [Related]
37. An ATP-sensitive potassium channel blocker suppresses sodium-induced hypertension through increased secretion of urinary kallikrein.
Kamata Y; Fujita T; Kato T; Hayashi I; Kurosaka M; Katori M; Fujita Y; Majima M
Hypertens Res; 2009 Mar; 32(3):220-6. PubMed ID: 19262486
[TBL] [Abstract][Full Text] [Related]
38. A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension.
Wang H; Long CL; Zhang YL
J Pharmacol Exp Ther; 2005 Mar; 312(3):1326-33. PubMed ID: 15525792
[TBL] [Abstract][Full Text] [Related]
39. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
[TBL] [Abstract][Full Text] [Related]
40. Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenone-induced motor and neurochemical alterations in rats.
Yang Y; Liu X; Long Y; Wang F; Ding JH; Liu SY; Sun YH; Yao HH; Wang H; Wu J; Hu G
J Neurosci Res; 2005 May; 80(3):442-9. PubMed ID: 15795934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
